Sage Therapeutics is rated a Strong Buy due to its undervaluation, trading below cash holdings, and potential in its drug pipeline, especially Zuranolone. Biogen's $7.22 per share buyout offer signals ...
Biogen to drive end-to-end development and commercialization of ThecaFlex DRx™, an investigational implantable device for intrathecal delivery of antisense oligonucleotides (ASOs) ThecaFlex DRx™ has ...
Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all approaching crucial trial readouts.
December 25, 2025, 8:37 PM ESTHealth Care November 30, 2025, 6:53 PM ESTTechnology November 24, 2025, 2:02 PM ESTHealth Care November 19, 2025, 9:57 AM ESTHealth Care November 13, 2025, 4:05 PM ...
Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its ...
Biogen is continuing to thin its pipeline, dropping a phase 2 program acquired in the $7.3 billion Reata Pharmaceuticals buyout and kicking early-stage Alzheimer’s and Parkinson’s prospects into touch ...
As momentum for Biogen’s newer drugs for neurological disorders builds at a slow and steady pace, it appears that the company can still count on its older products to hold down the fort and support ...
Please provide your email address to receive an email when new articles are posted on . Biogen Inc. and Neomorph Inc. have announced a partnership geared toward research and development of molecular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results